The 12 genes included ARID1A, ARID1B, BRIP1, NOTCH2, NOTCH4, EPHA5, ROS1, FAT1, SPEN, NSD1, PTPRT, and ZFHX3. Among them, only the mutation of ZFHX3 was associated with better OS in another pan-cancer cohort [MSKCC-Zehir cohort (13)] not receiving the ICB therapy (P = 0.007) (Supplementary Figure 1). The gene discussed is ROS1; the disease is cancer.